Reboxetine mesylate

CAS: 98769-84-7 货号: R409242 分子式: C19H23NO3·CH4O3S 分子量: 409.5 EC号: 638-822-2 PubChem CID: 127150
有货
级别和纯度: 10mM in DMSO
别名
甲磺酸瑞波西汀
储存条件
-80℃储存
运输条件
特低温运输
★
规格
库存
价格
数量
1ml
R409242-1ml
现货 Stock Image
¥408.90
请输入您要添加的产品数量

概述

Reboxetine mesylate是一种降低肾上腺素重新吸收的抑制剂,抑制[3H]小鼠下丘脑突触体对碘化钾的吸收量和[3H]5-HT小鼠纹状体突触对碘化钾吸收的Ki值分别为8.2nM和1070nM。A selective SLC6A2 inhibitor.

Information

Reboxetine (PNU 155950E) is anorepinephrinereuptake inhibitor withKiof 8.2 nM.
In vitro

Reboxetine dose-dependently and completely inhibits [3H]-dopamine uptake to the human norepinephrine transporters (hNET) with Ki value of 11 nM in Madin–Darby canine kidney (MDCK) cells.

In vivo

Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively. Reboxetine results in a significant reduction in the mean number of panic attacks and phobic symptoms in patients with DSM-III-R panic disorder. Reboxetine also results in improvement in Hamilton Rating Scale for Depression, Hopkins Symptom Checklist-90, and Sheehan Disability Scale scores. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex. Reboxetine dose dependently decreases nicotine self-administration by ~60%. Repeated administration of Reboxetine (5.6 mg/kg) decreases nicotine self-administration and sucrose-maintained responding across the 14 sessions.
Cell Data

cell lines:HDMECs

Concentrations:

Incubation Time:

Powder Purity:≥99%

规格

别名
甲磺酸瑞波西汀
英文别名
PNU 155950E, FCE20124 mesylate | Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (1:1)
规格或纯度
10mM in DMSO
英文名称
Reboxetine mesylate
生化机理
瑞波西汀(PNU 155950E)是一种去甲肾上腺素再摄取抑制剂,其Ki值为 8.2 nM。
储存条件
-80℃储存
运输条件
特低温运输
名称和识别符
EC号
638-822-2
分子类型
小分子
Isomeric SMILES
CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O
PubChem CID
分子量
409.5

高级数据

安全和危险性(GHS)
信号词
危险
危险声明

H302: 吞食有害

H360: 可能对生育能力或胎儿造成伤害

H373: 长期或反复接触可能对器官造成伤害

质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
溶液计算器